Skip to main content
Premium Trial:

Request an Annual Quote

ImmunoScape Raises $14M

NEW YORK — ImmunoScape, a Singapore-based developer of immune profiling technologies, said on Tuesday that it has raised $14 million in new funding.

The financing was led by Anzu Partners and included existing investor EDBI, an investment arm of the Economic Development Board of Singapore, and new investor Amgen Ventures.

ImmunoScape has developed a platform that uses proprietary combinatorial barcoding to enable the discovery and in-depth characterization of rare cancer-specific T cells at high resolution. According to the company, this allows for the simultaneous evaluation of tens of millions of T cells in blood samples from hundreds of cancer patients to identify rare, clinically relevant clones. The corresponding T-cell receptors (TCRs) are then evaluated and prioritized to build a diverse portfolio of TCR-T-cell therapies, it said.

"The new funding will allow us to expedite our development efforts and help us to advance our therapeutic candidates toward the clinic," ImmunoScape CEO Choon Peng Ng said in a statement.

About a year and a half ago, ImmunoScape raised $14 million to grow its team and help expand its presence in the US.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.